Searched for
COVAXIN TRIAL RESULTS
Report of CMC study on mixing vaccines likely by month-endIn heterologous doses' trials, a participant receives Covaxin followed by Covishield and vice versa. The Drug Controller General of India h...- Bharat Biotech claims 77.8% efficacy of Covaxin in phase-3 trialsAnnouncing the much awaited safety and efficacy data from phase-3 clinical trials of Covaxin, the IMCR director Prof Balram Bhargava said C...
- Bharat Biotech's Covaxin shows that it is 77.8% efficacy, gets SEC nodThe Subject Expert Committee (SEC) has reviewed Bharat Biotech’s data, and this will now be sent to the drug controller general of India fo...
- PIL against Covaxin trial on 2-18 age group: HC seeks Centre's standCovaxin, which has been indigenously developed by Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR), is be...
- Covaxin can neutralise double mutant variantPhase 3 clinical trials of Covaxin by Bharat Biotech International Ltd (BBIL) and ICMR have demonstrated 100% efficacy against severe Covid...
- Covaxin shows 100% efficacy against severe Covid-19, works well on variants“The tireless efforts of our scientists at ICMR and BBIL have resulted in a truly effective international vaccine of the highest standards ...
- Chhattisgarh government plans to allow use of Covaxin in state: MinisterTalking to , Singh Deo said, "We are considering allowing Covaxin for those who wish to opt for it after the Government of India dropped th...
- DGCI's Subject Expert Committee recommends waiving off 'clinical trial mode' from CovaxinAfter more than two hours of deliberation on Wednesday, the SEC in its recommendation to the drug regulator asked for the removal of clinic...
- Bharat Bio seeks review of clinical trial mode for Covaxin VaccineThe drug regulator’s subject expert committee (SEC) will meet on Thursday to consider the vaccine maker’s request and review the data. “The...
- Bharat Biotech approaches DCGI, seeks Covaxin's removal from 'clinical trial mode'The vaccine was granted approval “for restricted use in emergency situation in public interest as an abundant precaution, in clinical trial...
- Bharat Biotech's COVID-19 vaccine, Covaxin, has no serious side effects, says The LancetHowever, the report made it clear that efficacy cannot be determined by phase 2 trials and this required further corroboration with phase 3...
- No serious adverse events in Covaxin Phase 1 trialsBharat Biotech's indigenously developed Covid-19 vaccine, Covaxin, was well tolerated and did not report any serious adverse events during ...
- Covishield and Covaxin: All you need to know about the DCGI-approved vaccinesET rounds up facts and some questions on Covishield and Covaxin, approved by DCGI on Sunday
- A great milestone in India's scientific capability: Bharat Biotech on approval for emergency use of CovaxinThe approval of Covaxin for emergency use is a giant leap for innovation and novel product development in India, Krishna Ella, Chairman and...
- Bharat Biotech recruits 23,000 volunteers for Phase III trials of its coronavirus vaccineThe Phase III human clinical trials of Covaxin began mid-November, targeted to be done in 26,000 volunteers and it is the countrys first an...
- Bharat Biotech's Covaxin shows encouraging results in clinical trials: Research paperIn a double-blind, randomised, multi-centre phase 2 clinical trials, a total of 380 healthy children and adults were randomised and adminis...
- Covaxin COVID-19 vaccine's Phase III trial doesn't have enough takers, which could delay its roll out to the massesThe rollout of the Covid-19 vaccine by Bharat Biotech for the general public may get delayed as the All India Institute of Medical Sciences...
- Bharat Biotech looks to expand phase-III trial baseHyderabad-based Bharat Biotech is considering expanding phase-III trial of its Covid-19 vaccine candidate Covaxin by adding more sites to t...
- Bharat Biotech to begin final round of trials of Covaxin next monthThe regulator’s subject expert committee met on Tuesday and approved the phase-3 trial of the company’s indigenously developed vaccine cand...
- First part of phase-1 of Covaxin human trial completed at PGI Rohtak in HaryanaHuman trials of Covaxin, India's first vaccine candidate against coronavirus, began at PGI Rohtak on July 17. Three volunteers were adminis...
Load More
